MAG
PACB icon

Mass Ave Global’s Pacific Biosciences PACB Stock Holding History

Mass Ave Global’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-165,844
Closed -$733K – 44
2022
Q2 		$733K Buy
+165,844
New +$1.01M 0.2% 29

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mass Ave Global's PACB Position: Q3 2022 in Review

Mass Ave Global sold out of Pacific Biosciences (PACB) in Q3 2022, closing a stake of 165,844 shares — an estimated $733K sold.

Mass Ave Global first reported a position in PACB in Q2 2022 and held it in 1 quarter. The position peaked at $733K in Q2 2022. 227 funds tracked by Wall St. Rank hold PACB as of Q3 2022.

  • Mass Ave Global reported no remaining Pacific Biosciences position as of Q3 2022 after selling out during the quarter.
  • Mass Ave Global sold 165,844 Pacific Biosciences shares in Q3 2022, an estimated $733K.
  • Mass Ave Global first reported a position in Pacific Biosciences in Q2 2022 and held it in 1 quarter.
  • Mass Ave Global's Pacific Biosciences position peaked at $733K in Q2 2022.
  • 227 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2022.

Based on Mass Ave Global's 13F filing for Q3 2022, filed 14 Nov 2022.